AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9031450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 100 anti‐Xa units per kg body weight, administered subcutaneously after dose reduction
Number of subjects: 100
Study 9031450 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 12,500 i.u. subcutaneously every 12 h for 7 days, initiated 4 h after start of SK infusion
Number of subjects: 100
Study 8132379 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (50 mg/week)
Number of subjects: 7
Study 8132379 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg/week)
Number of subjects: 7
Study 8132379 — intervention group
Group type: COMPARATOR
Intervention: Control (sesame oil, 1 ml/week)
Number of subjects: 7
Study 2948735 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA (1.25 mg/kg iv over 3 hrs)
Number of subjects: 50
Study 2948735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2948735 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 50
Study 2948735 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and PTCA
Number of subjects: 50
Study 2948735 — intervention group
Group type: COMPARATOR
Intervention: t‐PA alone
Number of subjects: 50
Study 2948735 — intervention group
Group type: COMPARATOR
Intervention: t‐PA only
Number of subjects: 50
Study 31672928 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-Based Training (VBT)
Number of subjects: 27
Study 31672928 — intervention group
Group type: COMPARATOR
Intervention: Percentage-Based Training (PBT)
Number of subjects: 27
Study 28537849 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-chamber bag
Number of subjects: 240
Study 28537849 — intervention group
Group type: COMPARATOR
Intervention: Compounded monobag
Number of subjects: 240
Study 26044962 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent retrievers as device class
Number of subjects: 0
Study 26044962 — intervention group
Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 0
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in PD-IC group (2.43 ± 2.79)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in PD-MCI group (4.48 ± 4.33)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in frontal areas for PD-IC (1.09 ± 1.31)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in frontal areas for PD-MCI (1.83 ± 1.90)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in parietal areas for PD-IC (0.09 ± 0.29)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in parietal areas for PD-MCI (0.65 ± 1.03)
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DHs with age
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DHs with MMSE
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DHs with verbal fluency test
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DHs with orientation
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of DHs with executive function in CAMCOG-C
Number of subjects: 63
Study 23570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis of MMSE scores
Number of subjects: 63
Study 21605733 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 355
Study 21605733 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 355
Study 21605733 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 355
Study 19699531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg injection 1 week before surgery
Number of subjects: 68
Study 19699531 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 68
Study 19699531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 68
Study 16461054 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (1.8 g ecosapentaenoic acid and 1.2 g docosahexaenoic acid)
Number of subjects: 20
Study 16461054 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 20
Study 15266193 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean serum level 0.99 mEq/L)
Number of subjects: 40
Study 15266193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11785282 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering, ACE inhibition, avoidance of nephrotoxins
Number of subjects: 0
Study 11785282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 0
Study 11785282 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely involvement of specialized nephrology teams
Number of subjects: 0
Study 9549917 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 101
Study 9549917 — intervention group
Group type: COMPARATOR
Intervention: Traditional cotton swabs
Number of subjects: 101
Study 7834934 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 7834934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3413270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg)
Number of subjects: 72
Study 3413270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 3413270 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 72
Study 3413270 — intervention group
Group type: COMPARATOR
Intervention: Sober Type As
Number of subjects: 72
Study 31688306 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal preparation (myrrh, chamomile flowers, coffee charcoal)
Number of subjects: 38
Study 31688306 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine
Number of subjects: 38
Study 29802953 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged neuromuscular electrical stimulation (NMES) for 8 weeks, 40-min sessions, 5 days per week.
Number of subjects: 14
Study 29802953 — intervention group
Group type: COMPARATOR
Intervention: Control period (no NMES).
Number of subjects: 14
Study 28694151 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 109
Study 28694151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 109
Study 26173606 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy
Number of subjects: 446
Study 26173606 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 446
Study 23644731 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 sympathectomy
Number of subjects: 60
Study 23644731 — intervention group
Group type: COMPARATOR
Intervention: T3-T4 sympathectomy
Number of subjects: 60
Study 21732807 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme (14 weeks, 40 minutes per session, twice per week)
Number of subjects: 12
Study 21732807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 12
Study 21732807 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme
Number of subjects: 12
Study 19211823 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + vigorous-intensity exercise
Number of subjects: 112
Study 19211823 — intervention group
Group type: COMPARATOR
Intervention: CR only
Number of subjects: 112
Study 19211823 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + moderate-intensity exercise
Number of subjects: 112
Study 19211823 — intervention group
Group type: COMPARATOR
Intervention: CR only, CR + moderate-intensity exercise, CR + vigorous-intensity exercise
Number of subjects: 112
Study 16913215 — intervention group
Group type: EXPERIMENTAL
Intervention: Actimel
Number of subjects: 251
Study 16913215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 14983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate carcinoma with systematic sextant needle biopsy for men with elevated PSA levels and/or positive findings on digital rectal examination or transrectal ultrasound.
Number of subjects: 11210
Study 14983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative treatment offered to patients diagnosed with PAC.
Number of subjects: 11210
Study 14983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol effectiveness.
Number of subjects: 11210
Study 11282760 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 13
Study 9203228 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (100 micrograms/mg)
Number of subjects: 12
Study 9203228 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (200 micrograms/mg)
Number of subjects: 12
Study 9203228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7951859 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 65
Study 7951859 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical treatment without EIS
Number of subjects: 65
Study 3277876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 10
Study 3277876 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 75 mg
Number of subjects: 10
Study 3277876 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intramuscular analgesia
Number of subjects: 10
Study 29550891 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention delivered by nurses
Number of subjects: 60
Study 28723807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 80
Study 28723807 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study 25619170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 32
Study 25619170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23835546 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 36
Study 23835546 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 21443301 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with nicotine patch
Number of subjects: 385
Study 21443301 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring night smoking and sleep disturbance
Number of subjects: 385
Study 18156649 — intervention group
Group type: EXPERIMENTAL
Intervention: One-cell biopsy (group I)
Number of subjects: 592
Study 18156649 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-cell biopsy (group II)
Number of subjects: 592
Study 22329352 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation thalidomide and prednisolone
Number of subjects: 0
Study 16019280 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 0
Study 16019280 — intervention group
Group type: COMPARATOR
Intervention: Social‐ and computer‐contact control group
Number of subjects: 0
Study 14629244 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections (25 units into each corrugator supercilii muscle, total 50 units)
Number of subjects: 29
Study 14629244 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 29
Study 10454409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods in health technology assessment
Number of subjects: 0
Study 8665991 — intervention group
Group type: EXPERIMENTAL
Intervention: FER 5 mg 9 mm tablets
Number of subjects: 24
Study 8665991 — intervention group
Group type: EXPERIMENTAL
Intervention: FER 5 mg 11 mm tablets
Number of subjects: 24
Study 8665991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2213464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine 1:100,000
Number of subjects: 9
Study 2213464 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 9
Study 351351 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine
Number of subjects: 0
Study 351351 — intervention group
Group type: COMPARATOR
Intervention: Serology tests or attempted isolation of virus
Number of subjects: 0
Study 12222085 — intervention group
Group type: EXPERIMENTAL
Intervention: Various psychopharmacologic treatments (specific agents not mentioned)
Number of subjects: 0
Study 12222085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (specific agents not mentioned)
Number of subjects: 0
Study 12222085 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents (specific agents not mentioned)
Number of subjects: 0
Study 30896219 — intervention group
Group type: EXPERIMENTAL
Intervention: High patient-centered communication
Number of subjects: 231
Study 30896219 — intervention group
Group type: COMPARATOR
Intervention: Low patient-centered communication
Number of subjects: 231
Study 29358493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 12
Study 29358493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26842957 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 84
Study 26842957 — intervention group
Group type: COMPARATOR
Intervention: Older AEDs (carbamazepine or valproate sodium)
Number of subjects: 84
Study 24698829 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (Group B)
Number of subjects: 72
Study 24698829 — intervention group
Group type: COMPARATOR
Intervention: Herbal mouthwash (Group A)
Number of subjects: 72
Study 23265029 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.02 mg
Number of subjects: 250
Study 23265029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 250
Study 23265029 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 250
Study 23265029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg
Number of subjects: 250
Study 23265029 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 250
Study 20306569 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) midazolam orally (group M)
Number of subjects: 60
Study 20306569 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg kg(‐1) midazolam orally with parental presence (group MP)
Number of subjects: 60
Study 20306569 — intervention group
Group type: COMPARATOR
Intervention: Parental presence alone (group P)
Number of subjects: 60
Study 19093049 — intervention group
Group type: EXPERIMENTAL
Intervention: QuiXfil (Xeno III; Dentsply DeTrey)
Number of subjects: 43
Study 19093049 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram (Syntac Classic; Vivadent)
Number of subjects: 43
Study 19093049 — intervention group
Group type: EXPERIMENTAL
Intervention: QuiXfil
Number of subjects: 43
Study 19093049 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 43
Study 15813848 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-β 150 IU/kg three times weekly for 16 weeks
Number of subjects: 343
Study 15813848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 12508159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 DNA level
Number of subjects: 111
Study 12508159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level
Number of subjects: 111
Study 12508159 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious titer
Number of subjects: 111
Study 11034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 11034875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with valproate)
Number of subjects: 0
Study 11034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (in three patients with traumatic epilepsy)
Number of subjects: 0
Study 11034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping valproate administration
Number of subjects: 0
Study 8674327 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (pressor doses)
Number of subjects: 6
Study 8674327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3 micrograms/kg/min)
Number of subjects: 6
Study 8674327 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine + Dopamine (3 micrograms/kg/min)
Number of subjects: 6
Study 8674327 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 6
Study 1511816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal duct stent placement (10 patients)
Number of subjects: 19
Study 1511816 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 19
Study 6666689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 60
Study 6666689 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 60
Study 30451760 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral rectopexy
Number of subjects: 112
Study 30451760 — intervention group
Group type: COMPARATOR
Intervention: Stapled transanal rectal resection
Number of subjects: 112
Study 29903762 — intervention group
Group type: EXPERIMENTAL
Intervention: eGVHD App
Number of subjects: 78
Study 29903762 — intervention group
Group type: COMPARATOR
Intervention: No APP
Number of subjects: 78
Study 26645673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press training (TRA)
Number of subjects: 30
Study 26645673 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 24479897 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS (Single-Incision Laparoscopic Surgery)
Number of subjects: 42
Study 24479897 — intervention group
Group type: COMPARATOR
Intervention: FPLC (Four-Port Laparoscopic Cholecystectomy)
Number of subjects: 42
Study 21762279 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-enhanced diet for 5 days before surgery (Group 1, n=14)
Number of subjects: 39
Study 21762279 — intervention group
Group type: COMPARATOR
Intervention: No enteral feeding products before surgery (Group 2, n=12)
Number of subjects: 39
Study 21762279 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant therapy and no enteral feeding products before surgery (Group 3, n=13)
Number of subjects: 39
Study 20472263 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (4 mg twice daily)
Number of subjects: 0
Study 20472263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18048463 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT + PTA
Number of subjects: 56
Study 18048463 — intervention group
Group type: COMPARATOR
Intervention: OMT
Number of subjects: 56
Study 16234050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut/Coag output
Number of subjects: 267
Study 16234050 — intervention group
Group type: COMPARATOR
Intervention: Pure-Cut output
Number of subjects: 267
Study 16234050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 267
Study 11936554 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcement (NCR)
Number of subjects: 2
Study 10022187 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 40
Study 10022187 — intervention group
Group type: COMPARATOR
Intervention: Resin adhesive
Number of subjects: 40
Study 7774212 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (DO2 > or = 600 mL/min/m2)
Number of subjects: 89
Study 7774212 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed to achieve high DO2
Number of subjects: 89
Study 7774212 — intervention group
Group type: COMPARATOR
Intervention: Control group (DO2 450 to 550 mL/min/m2)
Number of subjects: 89
Study 7774212 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall myocardial infarction rate
Number of subjects: 89
Study 2079568 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-Interferon
Number of subjects: 0
Study 2079568 — intervention group
Group type: COMPARATOR
Intervention: Prednisone pretreatment
Number of subjects: 0
Study 6775687 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 0
Study 6775687 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 0
Study 30478888 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Number of subjects: 767
Study 30478888 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Telephone Support (STS)
Number of subjects: 767
Study 30478888 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 767
Study 30478888 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 767
Study 30478888 — intervention group
Group type: EXPERIMENTAL
Intervention: STS
Number of subjects: 767
Study 29185929 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiating diet (20-25% protein, 45-50% carbohydrate, 30-35% lipid; n=35)
Number of subjects: 69
Study 29185929 — intervention group
Group type: COMPARATOR
Intervention: Control diet (10-15% protein, 55-60% carbohydrate, 30% lipid; n=34)
Number of subjects: 69
Study 29185929 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiating diet
Number of subjects: 69
Study 29185929 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 69
Study 29185929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 69
Study 28384627 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous group (27 patients) received oral and intratympanic steroid injections for 2 weeks.
Number of subjects: 50
Study 28384627 — intervention group
Group type: COMPARATOR
Intervention: Sequential group (23 patients) treated with oral steroids for 2 weeks and intratympanic steroids for the subsequent 2 weeks.
Number of subjects: 50